

Prajapati ST, Pathak SP, Thakkar JH, Patel CN. Nanoemulsion based intranasal delivery of risperidone for nose to brain targeting. *Bull. Pharm. Res.* 2015;5(1):6-13.

### References (15):

1. Agrawal S, Giri TK, Tripathi DK, Ajazuddin, Alexander A. A review on novel therapeutic strategies for the enhancement of solubility for hydrophobic drugs through lipid and surfactant based self micro emulsifying drug delivery system: A novel approach. *Am. J. Drug Discov. Dev.* 2012;2(4):143-83.  
<http://scialert.net/abstract/?doi=ajdd.2012.143.183>
2. Basu S, Maity S. Preparation and characterisation of mucoadhesive nasal gel of venlafaxine hydrochloride for treatment of anxiety disorders. *Indian J. Pharma. Sci.* 2012;74(5):428-33.  
<http://www.ncbi.nlm.nih.gov/pubmed/23716871>
3. Behl CR, Pimplaskar HK, Sileno AP, deMeireles J, Romeo VD. Effects of physicochemical properties and other factors on systemic nasal delivery. *Adv. Drug Deliv. Rev.* 1998; 29(1-2):89-116.  
<http://www.sciencedirect.com/science/article/pii/S0169409X9700063X>
4. Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. *Int. Clin. Psychopharmacol.* 2008;23(4):209-15.  
<http://www.ncbi.nlm.nih.gov/pubmed/18545059>
5. Chouksey R, Jain AK, Pandey H, Maithil A. *In vivo* assessment of atorvastatin nanoemulsion formulation. *Bull. Pharm. Res.* 2011;1(2):10-4.  
<http://www.appconnect.in/app/journalUploads/FirstPagePreviewBPR-2-3.pdf>
6. DrugBank: Risperdone, DB00734  
<http://www.drugbank.ca/drugs/DB00734>
7. Kumar M, Misra A, Babbar AK, Pathak K, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. *Int. J. Pharm.* 2008; 358(1-2):285-91.  
<http://www.sciencedirect.com/science/article/pii/S0378517308002081>
8. Kumar M, Misra A, Mishra AK, Mishra P, Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. *J. Drug Target.* 2008; 16(10):806-14.  
<http://www.ncbi.nlm.nih.gov/pubmed/18988064>

9. Mishra DK, Kumar A, Raj R, Chaturvedi A. Capmul MCM based nanoemulsion for intranasal delivery of an antidepressant. *Bull. Pharm. Res.* 2013;3(1):34-9.  
<http://www.appconnect.in/wp-content/uploads/2011/03/ReprintBPR069.pdf>
10. Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. *Psychiatr. Serv.* 2005;56(3):273-82.  
<http://ps.psychiatryonline.org/doi/full/10.1176/appi.ps.56.3.273>
11. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. *FASEB J.* 2007;22(3):659-61.  
<http://www.ncbi.nlm.nih.gov/pubmed/17942826>
12. Soni V, Chourasia MK, Gupta Y, Jain A, Kohli DV, Jain SK. Novel approaches for drug delivery to the brain. *Ind. J. Pharm. Sci.* 2004;66(6):711-20.  
<http://cat.inist.fr/?aModele=afficheN&cpsidt=16587943>
13. Talegaonkar S, Mishra PR. Intranasal delivery: An approach to bypass the blood brain barrier. *Indian J. Pharmacol.* 2004;36(3):140-7.  
<http://www.ijp-online.com/article.asp?issn=0253-7613;year=2004;volume=36;issue=3;spage=140;epage=147;aulast=Talegaonkar>
14. Talegaonkar S, Tariq M, Alabood RM. Design and development of o/w nanoemulsion for the transdermal delivery of ondansetron. *Bull. Pharm. Res.* 2011;1(3):18-30.  
<http://www.appconnect.in/app/journalUploads/fpp-3-5.pdf>
15. Wermeling D, Miller J. Intranasal delivery of antipsychotic drug, United States Patent Application Publication, US 2006/0039869 A1, Feb 23, 2006.  
<http://patentimages.storage.googleapis.com/pdfs/US20060039869.pdf>

